
Sign up to save your podcasts
Or


In this episode, Dr. Russ Lebovitz, CEO of Amprion, explains why detecting misfolded proteins years before symptoms begin could completely reshape how we diagnose Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.
Â
He breaks down how early detection unlocks new possibilities for intervention, why alpha-synucleinis such a powerful biomarker, and what it really takes to commercialise a diagnostic platform in one of the toughest areas of biotech.
Â
Key Takeaways:
🔹Early detection is essential for slowing neurodegenerative diseases🔹Misfolded proteins can appear up to 20 years pre-symptom🔹Diagnostics commercialisation requires deep regulatory expertise🔹Partnerships like Amprion’s with Mayo Clinic accelerate scaling
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of DiagnosingDx, I’m joined by Wissam Hamou, Chief Operating Officer of One Biosciences, a company bringing single-cell diagnostics out of the lab and into real clinical practice.
We explore why single-cell analysis is finally ready for the clinic, how AI is unlocking insights that were previously impossible to see, and what this technology means for trials, treatment response, and the future of precision medicine.
Key Takeaways:
🔹 Single-cell technology is advancing toward real clinical validation, backed by fresh Series A funding.
🔹 AI is essential for making sense of the complex and high-dimensional data single-cell methods produce.
🔹 Cost, trust, and education remain key barriers to adoption among clinicians.
🔹 Regulatory clarity is urgently needed to establish standardized guidelines for single-cell assays.
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, I’m joined by Mustafa Al-Adhami, CEO and founder of Astek Consulting.
Â
We dive into how his team is building a rapid testing platform that can confirm a UTI, detect E. coli, and identify the right antibiotic within one hour -Â a breakthrough that has the potential to prevent sepsis and reshape frontline care.
Â
We also explore the realities of building a diagnostics company today, from navigating regulatory pathways to securing funding in a challenging market.
Â
Takeaways:
🔹Mustafa’s journey from refugee to diagnostics founder — and the mission driving Astek Consulting.
🔹How Astek’s rapid UTI platform delivers actionable, one-hour results.
🔹Why regulatory and reimbursement pathways must be built early to ensure adoption.
🔹The challenges of fundraising for diagnostics in the current environment.
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, I’m joined by Slava Akmaev, Chief AI Officer and COO at BPGbio, and one of the earliest pioneers applying AI to diagnostics and precision medicine.
We discuss how AI has evolved from early scepticism in pharma to becoming the operational backbone of modern biotech, how it’s reshaping clinical trial design and diagnostic development, and what it will take to rebuild investor confidence in the space.
Takeaways:
🔹How attitudes toward AI in diagnostics and drug development have shifted over the last decade.
🔹Where AI can remove bottlenecks in clinical trials and patient selection.
🔹Why integrating AI across teams, not just data science is now essential for life sciences companies.
🔹The role of diagnostics in enabling precision medicine at scale.
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, I sit down with Jenna Anderson, CEO of KiHealth, the company behind a breakthrough diagnostic test that can detect Type 1 diabetes years before symptoms appear.
We discuss how this innovation could transform preventative healthcare, why consumer empowerment is reshaping the industry, and how KiHealth is building a future where early detection becomes the norm.
Takeaways:
🔹Why COVID-19 changed how consumers think about their health.
🔹The growing role of preventative and accessible diagnostics.
🔹How healthcare marketing can catch up with other industries.
🔹Jenna’s vision for affordable, early disease detection.
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, I’m joined by Sally Bowden and BJ Kerns, founders of P3 Consulting, who help early-stage diagnostics startups navigate the realities of funding, regulation, and leadership.
Â
We unpack why so much innovation never makes it off the shelf, what investors expect before backing a product, and how founders can de-risk their science to survive in today’s challenging market.
Â
Takeaways:
🔹How funding constraints are reshaping diagnostics innovation.
🔹The growing importance of regulatory strategy and FDA engagement.
🔹Why strong leadership and clear product definition determine success.
🔹Signs of optimism emerging in the diagnostics market.
Â
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, I’m joined by Ben Casavant, Co-founder and CEO of Tasso, a company redefining how blood testing works.
Ben shares how a PhD side project turned into a diagnostics breakthrough, with over $120 million raised and more than two million patients served. He explains how Tasso’s painless, at-home blood collection device is making healthcare more accessible, and why innovation in something as simple as a blood draw was long overdue.
Key Takeaways:
🔹Tasso’s journey from PhD research to a global diagnostics company
🔹Making blood draws painless, patient-friendly, and scalable
🔹Lessons in iteration, team culture, and deep tech innovation
🔹Why failing fast can accelerate meaningful healthcare change
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, I’m joined by Julie Ballard, founder of Carrot Clinical and Tiger Team Bio, who has helped shape leading diagnostics companies including Genomic Health, GRAIL, and Guardant Health.Julie shares her journey from clinical laboratory scientist to entrepreneur and consultant, and what she’s learned from years of helping startups navigate the complex world of lab operations and regulatory compliance. She dives into the realities of LDT validation, the high stakes of hiring, and how even well-funded teams can make costly mistakes when moving too fast.Key Takeaways:• Transitioning from clinical science to entrepreneurship in diagnostics• Why quality systems are critical for lab operations• Common mistakes in LDT development and validation timelines• The growing focus on women’s health and new opportunities for founders🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
This week on Diagnosing Dx, I’m joined by Kaylene Ready, Chief Product Officer at Juniper Genomics, a company transforming the future of IVF through whole genome embryo testing.
We explore how Juniper is turning IVF from a 50/50 coin flip into a more certain path to success, empowering families with better information and outcomes. Kayleen also shares how her background in genetics and startup leadership fuels her mission to make fertility treatment more accessible and effective.
🔥 What You’ll Learn:
• How Juniper Genomics is improving IVF success rates through advanced genetic testing
• Why education and awareness are key to genetic testing adoption
• The role of genetic counselors in guiding patients and clinicians
• How startups like Juniper are making IVF more accessible and efficient
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
This week on Diagnosing Dx, I’m joined by Scott O’Brien, who helped lead GenMark from a small startup to a $1.8 billion acquisition by Roche.
Scott shares how his transition from science to commercial strategy shaped GenMark’s journey, the critical role of customer experience in competing against industry giants, and what it really takes to scale a diagnostics company through both breakthroughs and setbacks.
🔥 What You’ll Learn:
• How commercial strategy can define success in diagnostics
• The power of customer experience and retention in building long-term value
• Lessons from scaling a startup to a billion-dollar acquisition
• Why adaptability and feedback culture are key to growth
Whether you’re a founder, commercial leader, or diagnostics enthusiast, this conversation offers a rare inside look at the decisions that built one of the sector’s standout success stories.
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
From the publisher's feed